Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

238
The pathophysiology of pneumonia involves the following steps:
238
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

2.0K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
2.0K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

251
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
251
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

194
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
194
Common Respiratory Disorders01:31

Common Respiratory Disorders

384
Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
384
Pneumonia IV: Management01:28

Pneumonia IV: Management

315
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
315

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of sweat chloride in determining CFTR protein restoration in people with cystic fibrosis.

The Lancet. Respiratory medicine·2026
Same author

Residual disease activity in cystic fibrosis lung disease: implications for clinical management and research.

American journal of respiratory and critical care medicine·2026
Same author

Pulmonary exacerbations in patients with genetically confirmed PCD: a prospective observational multicentre study.

Frontiers in molecular biosciences·2026
Same author

Microbiome-Targeted Antibiotics Provide No Additional Microbiologic or Inflammatory Benefit during Cystic Fibrosis Pulmonary Exacerbations: Results from the CFMATTERS Trial.

American journal of respiratory and critical care medicine·2026
Same author

Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension study.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2026
Same author

Bridging the airway microbiome and targeted therapy in bronchiectasis: multi-omics insights, endotypes and emerging therapies.

The European respiratory journal·2026

Related Experiment Video

Updated: Jun 18, 2025

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic
09:03

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic

Published on: November 7, 2020

4.7K

COVID-19 in Pediatric Populations.

Yanki K Okuducu1, Marcus A Mall2, Lael M Yonker1

  • 1Department of Pediatrics, Pulmonary Division, Massachusetts General Hospital, 175 Cambridge Street, 5(th) floor, Boston, MA 02114, USA; Mucosal Immunology and Biology Research Center, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.

Clinics in Chest Medicine
|July 28, 2024
PubMed
Summary

The COVID-19 pandemic impacted children, with most infected by SARS-CoV-2. While children have immunity advantages, risks of severe disease and post-COVID complications like MIS-C and long COVID highlight vaccination importance.

Keywords:
COVID-19Long COVIDMultisystem inflammatory in childrenPediatric

More Related Videos

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.1K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

7.9K

Related Experiment Videos

Last Updated: Jun 18, 2025

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic
09:03

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic

Published on: November 7, 2020

4.7K
Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.1K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

7.9K

Area of Science:

  • Pediatric infectious diseases
  • Immunology
  • Public health

Background:

  • The COVID-19 pandemic altered the prevalence of respiratory viruses, with SARS-CoV-2 becoming dominant.
  • Over 96% of US children were infected with SARS-CoV-2 by 2023, with risk factors for severe disease identified.

Purpose of the Study:

  • To examine severe pediatric COVID-19 risks.
  • To compare SARS-CoV-2 with other respiratory viruses.
  • To explore age-specific immunoprotection and post-COVID complications in children.

Main Methods:

  • Review of existing literature on pediatric COVID-19.
  • Analysis of epidemiological data regarding SARS-CoV-2 infections in children.
  • Comparative analysis of viral characteristics and immune responses.

Main Results:

  • Children generally possess immunity advantages against severe COVID-19 compared to adults.
  • Genetic predispositions and comorbidities increase severe disease risk in pediatric populations.
  • Multisystem Inflammatory Syndrome in Children (MIS-C) and long COVID are significant post-acute sequelae.

Conclusions:

  • Vaccination is crucial for mitigating severe pediatric COVID-19 and its complications.
  • Understanding age-specific immunity is key to managing pediatric respiratory viral infections.
  • Continued research is needed on long-term effects and risk factors for severe outcomes.